How should I manage a patient with influenza A who is receiving ibrutinib for diffuse non‑Hodgkin lymphoma and is not neutropenic?

Management of Influenza A in a Patient on Ibrutinib for Diffuse NHL Without Neutropenia

Initiate oseltamivir 75 mg orally twice daily for 5 days immediately, without waiting for laboratory confirmation, and continue ibrutinib with heightened surveillance for bacterial and fungal superinfection. 1, 2

Antiviral Treatment

• Start oseltamivir 75 mg orally twice daily for 5 days as soon as influenza A is suspected or confirmed, ideally within 48 hours of symptom onset. 1, 2, 3
• Treatment within 48 hours reduces illness duration by approximately 1–1.5 days and cuts pneumonia risk by roughly 50%. 1, 2
• Do not delay antiviral therapy while awaiting laboratory confirmation during influenza season—rapid tests have limited sensitivity and delays reduce treatment effectiveness. 3
• Advise the patient to take oseltamivir with food to markedly reduce gastrointestinal side effects (nausea occurs in 10–15% of patients). 1, 3
• Adjust oseltamivir dose to 75 mg once daily if creatinine clearance is <30 mL/min. 1, 3

Ibrutinib Continuation and Drug Interactions

• Continue ibrutinib at the current dose unless severe complications develop. 4
• There are no significant drug-drug interactions between oseltamivir and ibrutinib—oseltamivir does not inhibit CYP3A4, the primary metabolic pathway for ibrutinib. 4
• Avoid azole antifungals (fluconazole, voriconazole, posaconazole) if empiric antifungal therapy becomes necessary, as these agents significantly increase ibrutinib levels through CYP3A4 inhibition and can cause severe toxicity. 4

Heightened Infection Surveillance

Patients on ibrutinib are at substantially increased risk for serious bacterial and invasive fungal infections (IFIs), even without neutropenia. 4, 5, 6, 7

Bacterial Superinfection Monitoring

• Instruct the patient to seek immediate medical attention if symptoms worsen after initial improvement—this biphasic pattern strongly suggests bacterial superinfection. 3
• Warning signs requiring urgent evaluation include: persistent fever beyond 5–7 days, increasing dyspnea, chest pain, purulent sputum, or altered mental status. 3
• If bacterial superinfection is suspected, initiate empiric antibiotics with co-amoxiclav or doxycycline (for penicillin allergy, use clarithromycin or a respiratory fluoroquinolone). 3
• Do not prescribe antibiotics for uncomplicated influenza without evidence of bacterial superinfection. 3

Invasive Fungal Infection (IFI) Surveillance

Ibrutinib-treated patients have a 2.4–12% incidence of proven or probable IFIs, with mortality rates of 10–69%. 4, 5, 7

• The majority of IFIs in ibrutinib-treated patients (62.5%) occur in the absence of classic risk factors (neutropenia, lymphopenia, high-dose corticosteroids). 7
• Aspergillus species account for 63% of IFIs, and Cryptococcus species for 26%; pulmonary involvement occurs in 69%, cranial involvement in 60%, and disseminated disease in 60%. 5
• Aspergillus and yeast infections typically occur within the first 6 months of ibrutinib therapy, while non-Aspergillus mold infections present as late-onset (>6 months). 4
• The median time from ibrutinib initiation to first serious infection is 125 days. 6

If respiratory symptoms persist or worsen despite oseltamivir, obtain:

• Chest CT scan (more sensitive than chest X-ray for early infiltrates). 4
• Serum galactomannan and β-D-glucan. 4
• Cryptococcal antigen testing. 4
• Consider brain MRI and lumbar puncture if any neurological symptoms develop, as ibrutinib-associated IFIs have high rates of CNS dissemination (22% cerebral involvement in some series). 4

Antifungal Prophylaxis Decision

• Routine primary antifungal prophylaxis is not recommended for ibrutinib monotherapy in the absence of additional risk factors. 4
• Consider individualized antifungal prophylaxis only if the patient has:
  • Previous IFI. 4
  • Recent salvage treatment following fludarabine-based therapy or alemtuzumab (within 3 months). 4
  • Concomitant high-dose corticosteroids. 4, 6
  • Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT), which increases serious infection risk 4.6-fold. 6
• If antifungal prophylaxis is indicated, avoid azole agents due to CYP3A4 interactions with ibrutinib; consider echinocandins or liposomal amphotericin B if prophylaxis is necessary. 4

Pneumocystis jirovecii Pneumonia (PJP) Prophylaxis

• PJP prophylaxis is not routinely recommended for ibrutinib monotherapy—the incidence of PJP is <3% with ibrutinib alone. 4
• Initiate PJP prophylaxis (trimethoprim-sulfamethoxazole or alternative) only if the patient is receiving or has recently received:
  • Prolonged high-dose corticosteroids. 4
  • Purine analogues (fludarabine, pentostatin). 4
  • Idelalisib. 4
  • Anti-CD20 antibodies (rituximab, obinutuzumab). 4

Supportive Care

• Adequate hydration and rest are essential. 3
• Antipyretics (acetaminophen or ibuprofen) for fever and myalgias. 3
• Cough suppressants for symptomatic relief. 3

Infection Control Measures

• Enforce strict hygiene precautions (hand washing, surgical masks) if the patient requires hospitalization. 4
• Restrict visitors with respiratory illness. 4
• Vaccinate household contacts and healthcare personnel against influenza to increase herd immunity and reduce transmission risk. 4

Future Vaccination Considerations

• Annual inactivated influenza vaccination is recommended for all patients on ibrutinib, although response rates are variable (5–74% seroprotection). 4
• Consider administering a second dose of influenza vaccine one month after the first dose to improve seroprotection rates in patients with CLL or NHL on ibrutinib. 4
• Vaccinate before starting ibrutinib if possible, as serological response to vaccines is extremely low once BTK inhibitor therapy is initiated. 4
• Avoid live attenuated influenza vaccine; only inactivated formulations should be used. 4

Common Pitfalls to Avoid

• Do not withhold oseltamivir if the patient presents >48 hours after symptom onset and is deteriorating or hospitalized—mortality benefit persists up to 96 hours. 1
• Do not assume the absence of neutropenia eliminates infection risk—ibrutinib causes profound immune dysfunction independent of neutrophil count. 7
• Do not prescribe azole antifungals empirically without considering ibrutinib dose reduction or temporary discontinuation—the combination can cause life-threatening ibrutinib toxicity. 4
• Do not delay diagnostic workup for IFI if respiratory symptoms persist beyond expected influenza course—early diagnosis is critical given the 10–69% mortality rate of ibrutinib-associated IFIs. 4, 5, 7